article thumbnail

How Value Based Health Care Will Impact Medical Sales

Spotio

The goals are to increase quality, decrease costs and turn health care into a competitive marketplace. They cite a 24% increase in drug costs per hospital admission in 2014 and a 12% increase in 2015. Home healthcare won’t directly impact medical device sales. Better health outcomes will drive sales.

article thumbnail

470% price increases

World of DTC Marketing

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Virtual Reality Training For Medical Device Sales Reps With David Howe

Evolve Your Success

Virtual reality is not just a game-changer for medical sales, but a life-changer for all of us. In this episode, Samuel Adeyinka interviews David Howe to explore the world of virtual reality training for medical device sales reps. I love talking about medical devices, software, sales and business. Samuel, I’m doing great.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.

Sales 76
article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 57
article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. ” Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS average at around 7%, before skyrocketing to 19% in 2022 ahead of a government agreed cap at 15%. The increase to 26.5%

Pharma 70
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). More recently, Biogen has been facing competition from dimethyl fumarate generics.